The US Food and Drug Administration (FDA) has delayed its decision on Stealth BioTherapeutics’ new drug application (NDA) for elamipretide, a treatment for the ultra-rare disease Barth syndrome.

The US Food and Drug Administration (FDA) has delayed its decision on Stealth BioTherapeutics’ new drug application (NDA) for elamipretide, a treatment for the ultra-rare disease Barth syndrome. The ...

Barth syndrome is caused by a mutation in the tafazzin gene, which results in reduced cardiolipin levels, a phospholipid that plays a major role in mitochondrial function. The disease is ...

the researchers used an advanced home-built microscope to look at single proteins on individual DNA molecules. That in itself is an impressive achievement, as Barth explains: "A single cell ...

A senior at Academy of Notre Dame, Katie Barth is a Global Citizen Scholar candidate, a Blue and Gold Key Society member, and active member of Mock Trial and Model UN clubs and started Academy of ...